newsfilter
← Latest News
Business Wire·

Cyteir Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

- Phase 2 dose identified for CYT-0851 and initiation activities ongoing for Phase 2 monotherapy expansion study and Phase 1/2 combination studies - Ended quarter with approximately $200 million in cash to continue to advance our pipeline and to fund